Albireo to Report Q1 2022 Financial Results on May 16
09 Mai 2022 - 2:30PM
Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company
developing novel bile acid modulators, today announced that
management will host a conference call and live audio webcast
at 4:30 p.m. ET on May 16, 2022, to provide a business
update and review the company’s financial results for the quarter
ended March 31, 2022.
To access the live conference call by phone, dial
877-407-0792 (domestic) or 201-689-8263 (international), and
provide the access code 13729296. A live audio webcast will be
accessible from the Investors page at ir.albireopharma.com/. To
ensure a timely connection to the webcast, it is recommended that
participants register at least 15 minutes prior to the scheduled
start time. An archived version of the webcast will be available
for replay on the Events & Presentations section of the
Investors page of Albireo’s website for 3 months following the
event.
About Albireo Albireo Pharma is a rare disease
company focused on the development of novel bile acid modulators to
treat rare pediatric and adult liver diseases. Albireo’s lead
product, Bylvay, was approved by the U.S. FDA as the first drug for
the treatment of pruritus in all types of progressive familial
intrahepatic cholestasis (PFIC), and it is also being developed to
treat other rare pediatric cholestatic liver diseases with Phase 3
trials in Alagille syndrome (ALGS) and biliary atresia, as well as
Open-label Extension (OLE) studies for PFIC and ALGS. In Europe,
Bylvay has been approved for the treatment of PFIC with pricing
listing in Germany and guidance from the National Institute for
Health and Care Excellence (NICE) recommending Bylvay for use in
the National Health Service in the England, Wales and Northern
Ireland UK. The Company has also completed a Phase 1 clinical trial
for A3907 to advance development in adult cholestatic liver
disease, with IND-enabling studies progressing with A2342 for viral
and cholestatic liver disease. Albireo was spun out from
AstraZeneca in 2008 and is headquartered in Boston, Massachusetts,
with its key operating subsidiary in Gothenburg, Sweden. For more
information on Albireo, please visit
www.albireopharma.com.
Media Contact:Colleen Alabiso,
857-356-3905, colleen.alabiso@albireopharma.comLance Buckley,
917-439-2241, lbuckley@lippetaylor.com Investor
Contact:Hans Vitzthum, LifeSci Advisors, LLC.,
617-430-7578
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Apr 2023 bis Apr 2024